Key points are not available for this paper at this time.
We found that the significant risk factor for CMV antigenemia in multivariate analysis was prior graft-versus-host disease (GVHD) experience and higher donor age. For high-level antigenemia, GVHD or duration of its treatment was significant determinant.
Hadjibabaie et al. (Fri,) studied this question.